November 17, 2011 – A new study has found that Multaq, the drug approved to treat patients whose hearts intermittently race with quick and inefficient contractions, doubled the risk of death in those with a permanent form of the erratic rhythm. The defective drug, manufactured by Sanofi, also caused an increase in stroke and heart failure rates among patients given Multaq during the trial. Doctors thought the drug would reduce deaths, strokes and hospitalizations in patients with more serious heart rhythms but have concluded that it would not.
In January, the FDA issued a warning to heart patients treating with Multaq (dronedarone) and health professionals about cases of rare, but severe liver injury resulting from taking the drug.
The Philadelphia personal injury attorneys at Messa & Associates are experienced at handling cases involving pharmaceutical and drug product injuries . Our skilled team of Pennsylvania injury attorneys has successfully pursued litigation and obtained verdicts and settlements for victims of defective drug injuries. If you or a loved one has suffered serious injury or death as a result of taking Multaq or another defective drug or medical device, please contact us at 1-877-MessaLaw.